Creutzfeldt-Jakob Disease (CJD): A Deadly Neurodegenerative Condition; Its Epidemiology, Monitoring, Current Status of Prevention and Circumvention

Authors

  • Yash Srivastav Azad Institute of Pharmacy and Research, Lucknow, UP, India
  • Abdul Hameed Azad Institute of Pharmacy and Research, Lucknow, UP, India

DOI:

https://doi.org/10.22270/ajprd.v12i6.1491

Abstract

Creutzfeldt-Jakob Disease CJDis a rare brain ailment that causes dementia. It is often referred to as Creutzfeldt-Jakob. It is a member of a class of illnesses called prion disorders that affect both humans and animals. Alzheimer's disease and Creutzfeldt-Jakob disease symptoms can be comparable.A rare yet deadly neurodegenerative condition is Creutzfeldt-Jakob disease (CJD). According to reports, it affects one in one to one and a half million people worldwide each year, with less than 1,000 cases occurring in the US.A deadly neurodegenerative condition, Creutzfeldt-Jakob disease (CJD) is also referred to as subacute spongiform encephalopathy or neurocognitive dysfunction caused by prion disease. Memory issues, behavioural changes, poor coordination, and visual impairments are some of the early indications. Dementia, uncontrollable movements, blindness, paralysis, and coma are later signs. Within a year, almost 70% of people pass away.In 1922, Walther Spielmeyer coined the term "Creutzfeldt–Jakob disease" in honour of the German neurologists Hans Gerhard Creutzfeldt and Alfons Maria Jakob. A protein called a prion folds abnormally to cause CJD. Misfolded proteins known as infectious prions can cause other misfolded proteins to do the same.People with CJD experience a variety of symptoms, such as uncontrollable muscle spasms or mobility issues, memory loss, and cognitive challenges. Because CJD causes so much damage, it is ultimately fatal.The diseases CJD and variant CJD (vCJD) are not the same, despite their very similar names. They're both prion illnesses. But eating meat from cows with bovine spongiform encephalopathy, also known as Mad Cow Disease, is linked to variant CJD. CJD mostly happens seldom and is sometimes referred to as "classic CJD" to prevent confusion.Although there isn't a known cure for Creutzfeldt-Jakob disease (CJD), the National Prion Clinic is doing clinical research to look at potential therapies. Currently, the goal of treatment is to keep the patient as comfortable as possible while using medications to lessen symptoms.The present state of Creutzfeldt-Jakob disease (CJD), its underlying causes, and possible treatments are assessed in this article.

 

Downloads

Download data is not yet available.

Author Biographies

Yash Srivastav, Azad Institute of Pharmacy and Research, Lucknow, UP, India

Azad Institute of Pharmacy and Research, Lucknow, UP, India

Abdul Hameed, Azad Institute of Pharmacy and Research, Lucknow, UP, India

Azad Institute of Pharmacy and Research, Lucknow, UP, India

References

Ishibashi D, Homma T, Nakagaki T, Fuse T, Sano K, Satoh K, et al. Type I interferon protects neurons from prions in in vivo models. Brain. 2019 Apr;142(4):1035–50.

Gao LP, Shi Q, Xiao K, Wang J, Zhou W, Chen C, et al. The genetic Creutzfeldt-Jakob disease with E200K mutation: analysis of clinical, genetic and laboratory features of 30 Chinese patients. Sci Rep. 2019 Feb;9(1):1836.

Navid J, Day GS, Strain J, Perrin RJ, Bucelli RC, Dincer A, et al. Structural signature of sporadic Creutzfeldt-Jakob disease. Eur J Neurol. 2019 Aug;26(8):1037–43.

Aslam S, Fritz MA, Cordes L, Sabbagh MN. What Promises the CJD Diagnosis in a Case of Rapidly Progressive Dementia? J Alzheimer’s Dis Park. 2018;8(5).

Sitammagari KK, Masood W. Creutzfeldt Jakob Disease. [Updated 2024 Jan 30]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK507860/. 2024;507860.

Satishchandra P, Shankar SK. Creutzfeldt-Jakob disease in India (1971-1990). Neuroepidemiology. 1991;10(1):27–32.

Rasheed U, Khan S, Khalid M, Noor A, Zafar S. A systemic analysis of Creutzfeldt Jakob disease cases in Asia. Prion [Internet]. 2024 Dec 31;18(1):11–27. Available from: https://doi.org/10.1080/19336896.2024.2311950

Klug GMJA, Wand H, Simpson M, Boyd A, Law M, Masters CL, et al. The intensity of human prion disease surveillance predicts observed disease incidence. J Neurol Neurosurg Psychiatry. 2013 Dec;84(12):1372–7.

Ladogana A, Puopolo M, Croes EA, Budka H, Jarius C, Collins S, et al. Mortality from Creutzfeldt-Jakob disease and related disorders in Europe, Australia, and Canada. Neurology. 2005 May;64(9):1586–91.

Johnson RT, Gonzalez RG, Frosch MP. Case records of the Massachusetts General Hospital. Case 27-2005. An 80-year-old man with fatigue, unsteady gait, and confusion. N Engl J Med. 2005 Sep;353(10):1042–50.

Mugilan SR, Joseph JP. A case of probable sporadic Creutzfeldt-Jacob Disease in a tertiary care hospital in Malaysia. Med J Malaysia. 2018 Dec;73(6):433–5.

Hayashi Y. Pathological and/or clinical work-ups are required in atypical Creutzfeldt-Jakob disease cases with periodic lateralised epileptiform discharge. Vol. 19, Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society. England; 2019. p. 519–20.

Duyckaerts C, Clavaguera F, Potier MC. The prion-like propagation hypothesis in Alzheimer’s and Parkinson’s disease. Curr Opin Neurol. 2019 Apr;32(2):266–71.

Brandel JP. [Prion diseases or transmissible spongiform encephalopathies]. La Rev Med interne. 2022 Feb;43(2):106–15.

Neshige S, Kuriyama M, Ota S. Journal of the Neurological Sciences Diffusion-weighted imaging findings predictive of postoperative recurrence of chronic subdural hematoma. J Neurol Sci [Internet]. 2024;467(November):123324. Available from: https://doi.org/10.1016/j.jns.2024.123324

Zhou B, Fukushima M, Alzheimer T, Initiative N. Journal of the Neurological Sciences Differential risk of Alzheimer’s disease in MCI subjects with elevated Abeta. 2024;467(November).

Miura Y, Ishibashi K. Journal of the Neurological Sciences Cerebellar type 1 metabotropic glutamate receptor availability decreases with disease progression in spinocerebellar ataxia type 6. J Neurol Sci [Internet]. 2024;467(November):123321. Available from: https://doi.org/10.1016/j.jns.2024.123321

Reyes Z, Catherine M, Punyamurthula S, Longo M, Maraganore D, Solch-ottaiano RJ. Journal of the Neurological Sciences The impact of gut microbiome and diet on post-acute sequelae of SARS-CoV-2 infection. J Neurol Sci [Internet]. 2024;467(November):123295. Available from: https://doi.org/10.1016/j.jns.2024.123295

Manco C, Plantone D, Righi D, Locci S, Bartalini S, Marconi R, et al. Journal of the Neurological Sciences Serum growth differentiation factor-15, glial fibrillary acidic protein, and neurofilament light chain : Their link and role in Creutzfeldt-Jakob disease. J Neurol Sci [Internet]. 2024;467(November):123305. Available from: https://doi.org/10.1016/j.jns.2024.123305

Uchida K, Bosshart S, Stebner A, Almekhlafi MA, Demchuk AM, Ganesh A, et al. Journal of the Neurological Sciences Prevalence of ipsilateral “ vulnerable carotid plaques with <50 % stenosis ” on CT angiography in embolic stroke of undetermined source. J Neurol Sci [Internet]. 2024;467(November):123316. Available from: https://doi.org/10.1016/j.jns.2024.123316

Maeda M, Kawahara T, Kubota A, Shimizu J, Toda T. Journal of the Neurological Sciences Prevalence and risk surveillance of anti-mitochondrial antibody-positive myositis : Outcomes of a nationwide survey. J Neurol Sci [Internet]. 2024;467(October):123287. Available from: https://doi.org/10.1016/j.jns.2024.123287

Eratne D, Kang MJY, Lewis C, Dang C, Malpas C, Ooi S, et al. Journal of the Neurological Sciences Plasma neurofilament light outperforms glial fibrillary acidic protein in differentiating behavioural variant frontotemporal dementia from primary psychiatric disorders. 2024;467(November).

Pioro EP, Rix B, Liu Y, Zhang J, Apple S. Journal of the Neurological Sciences Efficacy of Radicava ® IV ( intravenous edaravone ) in subjects with differing trajectories of disease progression in amyotrophic lateral sclerosis : Use of a novel statistical approach for post hoc analysis of a pivotal phase 3 clinical trial. J Neurol Sci [Internet]. 2024;467(November):123290. Available from: https://doi.org/10.1016/j.jns.2024.123290

Forner SA, Takada LT, Bettcher BM, Lobach I V, Tartaglia MC, Torres-Chae C, et al. Comparing CSF biomarkers and brain MRI in the diagnosis of sporadic Creutzfeldt-Jakob disease. Neurol Clin Pract. 2015 Apr;5(2):116–25.

Macfarlane RG, Wroe SJ, Collinge J, Yousry TA, Jäger HR. Neuroimaging findings in human prion disease. J Neurol Neurosurg Psychiatry. 2007 Jul;78(7):664–70.

Rudge P, Jaunmuktane Z, Hyare H, Ellis M, Koltzenburg M, Collinge J, et al. Early neurophysiological biomarkers and spinal cord pathology in inherited prion disease. Brain. 2019 Mar;142(3):760–70.

Kolářová K, Marešová M, Manďáková Z, Kynčl J. Prion diseases with a focus on Creutzfeldt-Jakob disease, a summary of the incidence of Creutzfeldt-Jakob disease in the Czech Republic over the last 17 years, 2000-2017. Epidemiol Mikrobiol Imunol Cas Spol pro Epidemiol a Mikrobiol Ces Lek Spol JE Purkyne. 2018;67(4):155–60.

Li JSY, Lim KC, Lim WEH, Chen RC. Clinics in diagnostic imaging (193). Sporadic Creutzfeldt-Jakob disease (sCJD). Singapore Med J. 2018 Dec;59(12):634–41.

Brown P, Gibbs CJJ, Rodgers-Johnson P, Asher DM, Sulima MP, Bacote A, et al. Human spongiform encephalopathy: the National Institutes of Health series of 300 cases of experimentally transmitted disease. Ann Neurol. 1994 May;35(5):513–29.

Todd N V, Morrow J, Doh-ura K, Dealler S, O’Hare S, Farling P, et al. Cerebroventricular infusion of pentosan polysulfate in human variant Creutzfeldt-Jakob disease. J Infect. 2005 Jun;50(5):394–6.

Ryan R, Hill S, Lowe D, Allen K, Taylor M, Mead C. Notification and support for people exposed to the risk of Creutzfeldt-Jakob disease (CJD) (or other prion diseases) through medical treatment (iatrogenically). Cochrane Database Syst Rev. 2011 Mar;(3):CD007578.

Tavares-Júnior JWL, Carvalho R de O, Feitosa RRP, Rolim F de PS, Rocha FA, Pitombeira MS, et al. Diagnostic approach in a patient with Creutzfeldt-Jakob disease. Vol. 16, Dementia &Neuropsychologia. Brazil; 2022. p. 361–4.

Published

2024-12-15

How to Cite

Yash Srivastav, & Abdul Hameed. (2024). Creutzfeldt-Jakob Disease (CJD): A Deadly Neurodegenerative Condition; Its Epidemiology, Monitoring, Current Status of Prevention and Circumvention. Asian Journal of Pharmaceutical Research and Development, 12(6), 125–130. https://doi.org/10.22270/ajprd.v12i6.1491